US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Poxel SA

0.2500

0.0000

Volume:- -

Turnover:- -

Market Cap:13.43M

PE:-0.63

High:0.2500

Open:0.2500

Low:0.2500

Close:0.2500

52wk High:0.2500

52wk Low:0.2500

Shares:53.73M

Float Shares:44.17M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.3971

EPS(LYR):-0.3971

ROE:-323.37%

ROA:-22.15%

PB:-0.19

PE(LYR):-0.63

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Poxel SA

Exchange:

EXPERT

Establishment Date:

2009

Employees:

6

Office Location:

Immeuble Le Sunway,259-261 Avenue Jean JaurEs,Lyon,Rhône-Alpes,France

Website:

- -

Zip Code:

69007

Phone:

33 1 44 71 94 94

Fax:

- -

Introduction:

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PXXLF/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PXXLF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PXXLF\",,,,,undefined,":{"symbol":"PXXLF","market":"US","secType":"STK","nameCN":"Poxel SA","latestPrice":0.25,"timestamp":1766429880000,"preClose":0.25,"halted":0,"volume":0,"delay":15,"floatShares":44171979,"shares":53729960,"eps":-0.39708,"marketStatus":"Trading","change":0,"latestTime":"12-22 13:58:00 EST Delay","open":0.25,"high":0.25,"low":0.25,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.39708,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1766437200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.25,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PXXLF\",,,,,undefined,":{"symbol":"PXXLF","floatShares":44171979,"roa":"-22.15%","roe":"-323.37%","lyrEps":-0.39708,"shares":53729960,"dividePrice":0,"high":0.25,"amplitude":0,"preClose":0.25,"low":0.25,"week52Low":0.25,"pbRate":"-0.19","psRate":"1.49","week52High":0.25,"institutionHeld":0,"latestPrice":0.25,"eps":-0.39708,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.39708,"open":0.25,"prevYearClose":0.25,"prevWeekClose":0.25,"prevMonthClose":0.25,"prevQuarterClose":0.25,"fiveDayClose":0.25,"twentyDayClose":0.25,"sixtyDayClose":0.25},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PXXLF\",params:#limit:5,,,undefined,":[{"date":"2022-11-08","symbol":"PXXLF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1667898000000,"name":null,"time":"","dateTimestamp":1667883600000,"actualEps":null},{"date":"2022-09-21","symbol":"PXXLF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1663747200000,"name":null,"time":"","dateTimestamp":1663732800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PXXLF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PXXLF\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":109129442,"yearFounded":2009,"employeeNum":6,"address":"Immeuble Le Sunway,259-261 Avenue Jean JaurEs,Lyon,Rhône-Alpes,France","zipCode":"69007","officePhone":"33 1 44 71 94 94"},"stockCompanyDetail":{"stockEarnings":[{"period":"1week","weight":-0.0012},{"period":"1month","weight":0.2227},{"period":"3month","weight":0.0478},{"period":"6month","weight":-0.1347},{"period":"1year","weight":0.1515},{"period":"ytd","weight":0.3817}],"description":"Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.","exchange":"EXPERT","name":"Poxel SA","nameEN":"Poxel SA"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"PXXLF\",market:\"US\",,,undefined,":null}}